March 4th, 2021 | 09:16 CET
NanoRepro, EXMceuticals, Deutsche Telekom - The profiteers of the new world!
Table of contents:
The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.
The rocket ignites
You can tell this stock market story to your grandchildren one day. It's the incredible story of NanoRepro, a Marburg-based Company that was initially in the self-diagnostics business and had 25 rapid tests in its portfolio - including an HIV test, two pregnancy tests and five others purely for medical use. In 2019, the Marburg-based Company generated annual sales of EUR 1.2 million. The Company saw its opportunity in the Corona pandemic. Already in October 2020, sales exploded due to the antigen tests offered by NanoRepro. Now the Marburg-based Company is thick in business with the Corona rapid tests. The Company recently concluded a cooperation with ViroMed.
The Hamburg-based Company buys Corona antigen rapid tests from the anterior nasal swab in a volume of around EUR 30 million from NanoRepro. In addition, NanoRepro has been added to the list of approved "antigen tests" of the German Federal Institute for Drugs and Medical Devices (BfArM). The Company could receive a further boost if approval were granted for self-testing by laymen. We assume that rapid tests will become established in our lives, at least in the near future. However, the competition here is becoming increasingly fierce. The share price, which was still below EUR 2.0 last year, has since increased tenfold and reached an all-time high of EUR 22.40, corresponding to a market capitalization of approximately EUR 1.5 billion and a stock market value of around EUR 185 million. It smells like overheating!
Revolutionary merger announced
Things could go similarly fast as with NanoRepro at medical cannabis Company EXMceuticals. While last year it was still researching a disinfectant to combat the Coronavirus under the auspices of the European Union, among others, a milestone in the history of the young Canadian Company was sealed yesterday. Originally, EXMceuticals' goal was to become a large-scale producer of high-quality cannabis ingredients for the pharmaceutical market. To this end, the Canadian-based Company has positioned itself in the European market and owns an EU-certified processing facility in Portugal to extract active ingredients from cannabis plants. Access to the European market now becomes key to the forward-looking transaction.
Big player emerges
EXMceuticals plans to merge with Global Cannabinoids, a leading US B2B distributor of hemp-derived cannabinoids and finished products in bulk and wholesale. Upon completing the merger, a top hemp and cannabinoid-based product distribution company will be created, operating under GC. The merger will create a player with an unprecedented platform to serve the rapidly growing global market of cannabinoid-based products. In 2027, the global CBD industry is expected to reach USD 123 billion in sales. In the US, Global Cannabinoid currently serves over 70,000 customers with over 1,000 units of product inventory.
Portugal's license will allow the future global player to roll out its distribution to the rapidly growing European market. A private placement of up to CAD 6.0 million is also planned. The net proceeds will be used to fund the merger, the pro forma business plan and general corporate purposes. The CBD market is still in the early stages of growth, particularly in Europe. The merger should enable GC to gain market share globally. EXMceuticals is listed in Frankfurt and was traded at EUR 0.135 before it got halted and has a market capitalization of just under EUR 8.0 million. A very interesting growth story is emerging here!
Do it again...and better!
Deutsche Telekom dares once again to control Corona through technology. After the somewhat subdued success in developing the Corona warning app together with the software provider SAP, which has been downloaded 26 million times and the benefits are not yet fully known, the Bonn-based Company wants to develop the long-awaited vaccination certificate for Germany. According to the Company's headquarters, a proposal has been sent to the German Federal Ministry of Health. The vaccination passport is to pursue the goal that travel can be revived in the Corona Crisis.
The Ministry of Health's goal is to have a finished vaccination passport available before the summer vacation. The software giant SAP did not throw its hat into the ring this time. This time, a shareholding by the US group Microsoft might be a possibility. The Deutsche Telekom share continued its upward trend, which began in March 2020, and yesterday traded at EUR 10.58, up 0.90%. The next resistance is at EUR 11.0. Should these be broken through, the next price target would be EUR 13.0.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.